文献速递类风湿关节炎

达标治疗策略在老年起病类风湿关节炎中的3年疗效与安全性

Effectiveness and safety of treat-to-target strategy in elderly-onset rheumatoid arthritis: a 3-year prospective observational study.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

本研究对197例未使用过甲氨蝶呤的老年起病类风湿关节炎(EORA)患者随访3年,评估以低疾病活动度为目标的达标治疗(T2T)策略。结果显示,坚持T2T的患者SDAI缓解率和HAQ-DI≤0.5的比例显著高于未坚持者,且甲氨蝶呤、生物制剂和糖皮质激素未增加严重不良事件风险。

要点

  • 坚持T2T的EORA患者3年SDAI缓解率达57.8%,未坚持者仅34.8%。
  • 坚持T2T者3年HAQ-DI≤0.5的比例为70.3%,显著高于未坚持者的43.5%。
  • 调整疾病活动和合并症后,甲氨蝶呤、生物制剂及糖皮质激素与严重不良事件无显著关联。

核心结论

  • 采用甲氨蝶呤和生物制剂的T2T策略对EORA有效且安全性可接受,坚持T2T可获得更好结局。

研究设计与样本

  • 为期3年的前瞻性观察性研究,纳入197例未使用过甲氨蝶呤的中高疾病活动度EORA患者(平均年龄74.9岁)。
  • 在第12、24、36、52、76、104和128周评估T2T未执行情况。
  • 采用贝叶斯分层逻辑回归模型分析2122个3个月期间,评估甲氨蝶呤、生物制剂和糖皮质激素的风险。

主要发现

  • 84.7%的患者接受甲氨蝶呤,34.0%接受糖皮质激素联合DMARDs,41.6%接受生物制剂。
  • 197例中69例因合并症或个人决定未坚持T2T:33例1次、19例2次、10例3次、6例4次及以上。
  • 坚持T2T的128例患者中,3年SDAI缓解率和HAQ-DI≤0.5分别为57.8%和70.3%;未坚持的69例分别为34.8%和43.5%,差异显著。
  • 调整观察期间平均SDAI和基线合并症后,甲氨蝶呤、生物制剂和糖皮质激素与严重不良事件无显著关联。

关键数值与推荐

  • T2T目标为低疾病活动度,治疗调整顺序为传统合成DMARDs后生物制剂DMARDs。
  • 3年SDAI缓解率:坚持T2T者57.8% vs 未坚持者34.8%,差异显著。
  • 3年HAQ-DI≤0.5比例:坚持T2T者70.3% vs 未坚持者43.5%,差异显著。

临床怎么用

  • 对EORA患者可实施以低疾病活动度为目标的T2T策略,使用甲氨蝶呤和生物制剂。
  • 应关注合并症和患者意愿对T2T坚持性的影响,坚持T2T与更好的缓解和功能结局相关。
  • 在调整疾病活动和合并症后,甲氨蝶呤、生物制剂和糖皮质激素未显示增加严重不良事件风险。

局限性

  • 本研究为观察性研究,非随机对照设计。
  • 未坚持T2T的原因包括合并症和患者个人决定,可能存在混杂。
  • 严重不良事件分析基于3个月期间,可能受时间依赖的疾病活动影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate 3-year outcomes of following a treat-to-target (T2T) strategy targeting low disease activity for patients with elderly-onset RA (EORA) and to confirm safety profile of T2T. METHODS: Treatment was adjusted to target low disease activity with conventional synthetic DMARDs, followed by biologic DMARDs (bDMARDs) in 197 MTX-naïve EORA patients (mean age 74.9 years) with moderate-to-high disease activity. Non-implementation of T2T was evaluated at week 12, 24, 36, 52, 76, 104 and 128. To evaluate risks of using MTX, bDMARDs and glucocorticoids, 2122 periods of 3 months each were analysed using Bayesian hierarchical logistic regression models. RESULTS: Of the patients, 84.7% received methotrexate, 34.0% glucocorticoids with DMARDs and 41.6% bDMARDs during the observation period. Sixty-nine of the 197 patients failed to adhere to T2T because of comorbidities or the patient's own decision: 33 failed once, 19 twice, 10 three times and 6 four times or more. Simplified disease activity index (SDAI) remission and HAQ Disability Index (HAQ-DI) ≤0.5 at 3 years were achieved in 57.8% and 70.3% of the 128 patients adhering to T2T, and 34.8% and 43.5% of the 69 patients who did not adhere to T2T, respectively, and these were significantly different. Eighty-nine serious adverse events (SAEs) of any type were reported in 61 patients. MTX, bDMARDs and glucocorticoid were not associated with SAEs when adjusted for mean SDAI during the observation period and comorbidities at baseline. CONCLUSION: T2T strategy for EORA by using MTX and bDMARDs was effective with an acceptable safety profile. Adhering to T2T led to better outcomes.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Sugihara T, Ishizaki T, Onoguchi W, et al. Effectiveness and safety of treat-to-target strategy in elderly-onset rheumatoid arthritis: a 3-year prospective observational study. Rheumatology (Oxford). 2021. PMID: 33410490. doi:10.1093/rheumatology/keaa922

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。